Sunrise Air: What FDA Clearance for a Rechargeable Chin-Worn Sleep Test Actually Means

Belgium-based Sunrise has received FDA clearance for Sunrise Air, a rechargeable at-home sleep apnea test that expands on the company’s earlier mandibular jaw movement (MJM) platform with integrated airflow sensors, pulse oximetry, and audio capture. The clearance matters for anyone evaluating home sleep diagnostics because it addresses the most significant limitation of the original device: a single-biosignal approach that missed the multi-channel data clinical sleep labs use to classify apnea type.

The MJM Foundation

Sunrise’s core technology records mandibular jaw movements — the forward-backward and lateral motion of the jaw during sleep — as a proxy biosignal for respiratory events. When airway obstruction causes an apnea or hypopnea, jaw movement changes measurably. The MJM approach has peer-reviewed validation and has been FDA-cleared in its earlier form since 2023, but the original device relied primarily on jaw movement data, which is sensitive but not always sufficient to distinguish between obstructive and central apnea — a clinically important distinction that changes treatment decisions.

Sunrise Air adds thermistors for nasal/oral airflow measurement, an optical module for SpO2 and pulse rate, and an embedded microphone for snoring pattern analysis. The result is a multi-channel diagnostic dataset that supports AI algorithm classification of respiratory events across the same signal dimensions clinical polysomnography uses.

What the New Design Changes

The rechargeable form factor is more operationally significant than it might appear. The original Sunrise sensor used disposable adhesive patches that required replacement between study nights. Multi-night home sleep testing is clinically valuable — a single night captures 20-30% fewer respiratory events than a two-night average — but disposable components add per-night cost and patient friction that reduces compliance in real-world use.

Sunrise Air eliminates the disposable component loop. The sensor attaches to the chin, charges between uses, and can be deployed across multiple nights without additional cost or resupply. For sleep clinics managing home study inventory, this changes the economics of multi-night protocols. For individual consumers purchasing the device for personal use through Sunrise’s direct channel, multi-night testing becomes practical rather than expensive.

The AI-supported algorithms generate a clinical sleep report for physician review rather than a consumer wellness summary. This positions Sunrise Air within the same clinical workflow as prescription-only home sleep apnea tests (HSATs) rather than the consumer wearable category, where sleep quality scores provide behavioral feedback but not diagnostic data.

The Biohacker Relevance

For practitioners tracking sleep architecture as a longevity biomarker — a well-supported category, given the evidence connecting sleep-disordered breathing to cardiovascular risk, cognitive decline risk, and metabolic dysregulation — the question home devices historically struggled to answer was: is this poor-quality sleep data showing real pathology, or noise? The sleep priority-practice gap is well-documented; a device that can distinguish pathology from behavioral factors closes a meaningful diagnostic loop. Sunrise Air’s multi-channel design closes that gap for a device that doesn’t require a sleep lab appointment or a prescription referral to access.

The device is available through healthcare provider channels and Sunrise’s direct website. Pricing for consumer access has not been publicly announced. Sleep apnea has an estimated diagnosis gap: roughly 85% of moderate-to-severe cases remain undiagnosed, and access to convenient, clinically valid testing is the primary structural barrier. Consult a qualified healthcare provider before beginning any sleep apnea diagnostic or treatment protocol.

Source: Longevity.Technology

Content created with AI assistance and reviewed for accuracy.